Tag: CD30-expressing
FDA Approves Label Expansion for Brentuximab Vedotin
The approval of brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of adult patients with primary cutaneous anaplastic Large cell lymphoma or pcALC, which...
To Reimburse or not to Reimburse – That is the Question
Novel, innovative (bio)pharmaceutical drugs are an important part of our global healthcare system, offering advanced, radical new personalized and targeted therapy options to patients...
Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...
Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy. Oral...
